MA47167A - Composés pyrazolopyrimidine et leurs procédés d'utilisation - Google Patents
Composés pyrazolopyrimidine et leurs procédés d'utilisationInfo
- Publication number
- MA47167A MA47167A MA047167A MA47167A MA47167A MA 47167 A MA47167 A MA 47167A MA 047167 A MA047167 A MA 047167A MA 47167 A MA47167 A MA 47167A MA 47167 A MA47167 A MA 47167A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- pyrazolopyrimidine compounds
- pyrazolopyrimidine
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016112932 | 2016-12-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47167A true MA47167A (fr) | 2019-11-06 |
Family
ID=61094385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047167A MA47167A (fr) | 2016-12-29 | 2017-12-22 | Composés pyrazolopyrimidine et leurs procédés d'utilisation |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11155557B2 (fr) |
| EP (1) | EP3562809B1 (fr) |
| JP (1) | JP6900491B2 (fr) |
| KR (1) | KR20190100337A (fr) |
| CN (1) | CN110114343B (fr) |
| AU (1) | AU2017385543A1 (fr) |
| BR (1) | BR112019013287A2 (fr) |
| CA (1) | CA3046435A1 (fr) |
| CL (1) | CL2019001694A1 (fr) |
| CO (1) | CO2019006220A2 (fr) |
| CR (1) | CR20190310A (fr) |
| IL (1) | IL267671A (fr) |
| MA (1) | MA47167A (fr) |
| MX (1) | MX2019007339A (fr) |
| PE (1) | PE20191236A1 (fr) |
| PH (1) | PH12019501022A1 (fr) |
| RU (1) | RU2019123319A (fr) |
| UA (1) | UA122851C2 (fr) |
| WO (1) | WO2018122212A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20190310A (es) | 2016-12-29 | 2019-08-21 | Hoffmann La Roche | Compuestos de pirazolopirimidina y métodos de uso de los mismos |
| RU2769696C2 (ru) | 2017-05-22 | 2022-04-05 | Ф. Хоффманн-Ля Рош Аг | Терапевтические соединения и композиции и способы их применения |
| EP3740488A1 (fr) * | 2018-01-15 | 2020-11-25 | F. Hoffmann-La Roche AG | Composés pyrazolopyrimidine utilisés en tant qu'inhibiteurs de jak |
| CN114008050B (zh) * | 2019-06-18 | 2024-12-31 | 豪夫迈·罗氏有限公司 | Jak激酶的吡唑并嘧啶芳基醚抑制剂及其用途 |
| PE20220577A1 (es) | 2019-06-18 | 2022-04-20 | Hoffmann La Roche | Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos |
| TW202115069A (zh) | 2019-06-18 | 2021-04-16 | 瑞士商赫孚孟拉羅股份公司 | Ｊａｋ激酶之經四唑取代之吡唑并嘧啶抑制劑及其用途 |
| WO2022175829A1 (fr) * | 2021-02-17 | 2022-08-25 | Cellix Bio Private Limited | Formulations et compositions topiques |
| EP4583977A1 (fr) * | 2022-09-09 | 2025-07-16 | Chiesi Farmaceutici S.p.A. | Dérivés hétérocycliques comme inhibiteurs de janus kinase |
| CA3266831A1 (fr) * | 2022-09-09 | 2024-03-14 | Chiesi Farmaceutici S.P.A. | Dérivés hétérocycliques comme inhibiteurs de janus kinase |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| AU6311996A (en) | 1995-07-06 | 1997-02-05 | Zeneca Limited | Peptide inhibitors of fibronectine |
| US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| EP1241176A1 (fr) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Dérivés de purine pour le traitement de l'ischémie |
| JP4486817B2 (ja) | 2001-12-20 | 2010-06-23 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | １，４−ジヒドロ−１，４−ジフェニルピリジン誘導体 |
| SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
| CN102127078A (zh) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| RU2560153C2 (ru) | 2008-06-20 | 2015-08-20 | Дженентек, Инк. | Триазолпиридиновые соединения, ингибирующие jak, и способы |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| PE20211782A1 (es) | 2014-05-23 | 2021-09-08 | Hoffmann La Roche | Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos |
| TW201720828A (zh) | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
| EP3416967B1 (fr) | 2016-02-18 | 2022-02-09 | F. Hoffmann-La Roche AG | Composés thérapeutiques, leurs compositions et méthodes d'utilisation |
| JP7208020B2 (ja) | 2016-06-29 | 2023-01-18 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン誘導体、その結合体、及びそれを含む組成物、並びにその治療的用途 |
| CR20190310A (es) | 2016-12-29 | 2019-08-21 | Hoffmann La Roche | Compuestos de pirazolopirimidina y métodos de uso de los mismos |
-
2017
- 2017-12-22 CR CR20190310A patent/CR20190310A/es unknown
- 2017-12-22 UA UAA201907278A patent/UA122851C2/uk unknown
- 2017-12-22 PE PE2019001227A patent/PE20191236A1/es unknown
- 2017-12-22 RU RU2019123319A patent/RU2019123319A/ru not_active Application Discontinuation
- 2017-12-22 EP EP17836033.5A patent/EP3562809B1/fr active Active
- 2017-12-22 WO PCT/EP2017/084569 patent/WO2018122212A1/fr not_active Ceased
- 2017-12-22 MX MX2019007339A patent/MX2019007339A/es unknown
- 2017-12-22 BR BR112019013287A patent/BR112019013287A2/pt not_active Application Discontinuation
- 2017-12-22 JP JP2019535901A patent/JP6900491B2/ja not_active Expired - Fee Related
- 2017-12-22 MA MA047167A patent/MA47167A/fr unknown
- 2017-12-22 CN CN201780081495.7A patent/CN110114343B/zh not_active Expired - Fee Related
- 2017-12-22 CA CA3046435A patent/CA3046435A1/fr not_active Abandoned
- 2017-12-22 AU AU2017385543A patent/AU2017385543A1/en not_active Abandoned
- 2017-12-22 KR KR1020197022055A patent/KR20190100337A/ko not_active Ceased
-
2019
- 2019-05-08 PH PH12019501022A patent/PH12019501022A1/en unknown
- 2019-06-14 CO CONC2019/0006220A patent/CO2019006220A2/es unknown
- 2019-06-19 CL CL2019001694A patent/CL2019001694A1/es unknown
- 2019-06-25 US US16/452,058 patent/US11155557B2/en not_active Expired - Fee Related
- 2019-06-26 IL IL267671A patent/IL267671A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019007339A (es) | 2019-09-06 |
| US20190345165A1 (en) | 2019-11-14 |
| JP6900491B2 (ja) | 2021-07-07 |
| PH12019501022A1 (en) | 2019-12-16 |
| RU2019123319A (ru) | 2021-02-01 |
| KR20190100337A (ko) | 2019-08-28 |
| CN110114343A (zh) | 2019-08-09 |
| CR20190310A (es) | 2019-08-21 |
| AU2017385543A1 (en) | 2019-05-23 |
| CA3046435A1 (fr) | 2018-07-05 |
| CN110114343B (zh) | 2022-09-06 |
| BR112019013287A2 (pt) | 2019-12-24 |
| PE20191236A1 (es) | 2019-09-11 |
| EP3562809B1 (fr) | 2021-06-09 |
| EP3562809A1 (fr) | 2019-11-06 |
| UA122851C2 (uk) | 2021-01-06 |
| CO2019006220A2 (es) | 2019-06-28 |
| JP2020503339A (ja) | 2020-01-30 |
| IL267671A (en) | 2019-08-29 |
| CL2019001694A1 (es) | 2019-11-22 |
| US11155557B2 (en) | 2021-10-26 |
| RU2019123319A3 (fr) | 2021-02-01 |
| WO2018122212A1 (fr) | 2018-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3504213A4 (fr) | Composés amino-pyrrolopyrimidinone et leurs procédés d'utilisation | |
| EP3429635A4 (fr) | Composés anti-crispr et leurs procédés d'utilisation | |
| EP3436048A4 (fr) | Néoantigènes et leurs procédés d'utilisation | |
| EP3684364A4 (fr) | Pyridazinones et leurs procédés d'utilisation | |
| MA47167A (fr) | Composés pyrazolopyrimidine et leurs procédés d'utilisation | |
| EP3436030A4 (fr) | Récepteurs chimériques et leurs procédés d'utilisation | |
| EP3429596A4 (fr) | Composés di-nucléotides cycliques et leurs procédés d'utilisation | |
| EP3510040A4 (fr) | Inhibiteurs d'éctonucléotidase et leurs procédés d'utilisation | |
| EP3435956A4 (fr) | Compositions photo-stabilisées et leurs procédés d'utilisation | |
| MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA46565A (fr) | Oxystérols et leurs procédés d'utilisation | |
| EP3298168A4 (fr) | Agents réducteurs stabilisés et leurs procédés d'utilisation | |
| EP3416634A4 (fr) | Agents immunomodulateurs et leurs procédés d'utilisation | |
| EP3307762A4 (fr) | Variants de cas9 rapporteurs et leurs procédés d'utilisation | |
| EP3383914A4 (fr) | Anticorps anti-ox40 et leurs procédés d'utilisation | |
| EP3319612A4 (fr) | Oxystérols et leurs procédés d'utilisation | |
| EP3319610A4 (fr) | Oxystérols et leurs procédés d'utilisation | |
| EP3394065A4 (fr) | Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés | |
| MA43284A (fr) | Composés et leurs méthodes d'utilisation | |
| MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
| MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
| EP3303435A4 (fr) | Hydrofluoroléfines et procédés d'utilisation associés | |
| EP3341027A4 (fr) | Complexes de transfection et leurs procédés d'utilisation | |
| MA39915B1 (fr) | Composés de pladiénolide pyridine et leurs procédés d'utilisation | |
| MA46546A (fr) | Composés thérapeutiques et leurs procédés d'utilisation |